At the news
? NEUTRALIMPACT 4/10 SC 13G filed Nov 6, 2026 at 10:58 ET
T. Rowe Price Investment Management filed a Schedule 13G disclosing a 8.2% passive stake in Xenon Pharmaceuticals as of September 30, 2026, representing 7,905,757 shares. This is a new 13G filing by T. Rowe Price, indicating a significant passive institutional position in the biotech company.
- T. Rowe Price Investment Management disclosed beneficial ownership of 7,905,757 shares of Xenon Pharmaceuticals common stock as of September 30, 2026
- The stake represents 8.2% of outstanding shares
- The filing is a new Schedule 13G, not an amendment
- T. Rowe Price certifies passive intent under Rule 13d-1(b)
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access